| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Afuresertib | GSK-2110183; GSK-2110183B; GSK-2110183C; GSK-21110183; LAE-002; LAE002; ASB-183 | Phase 3 Clinical | Glaxosmithkline Plc, Novartis Pharma Ag | Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Hematologic Neoplasms; Histiocytosis, Langerhans-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Metastatic breast cancer; Multiple Myeloma; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| Ipatasertib | RG-7440; GCD-0068; GDC-0068; RO-5532961 | Phase 3 Clinical | Array Biopharma, Genentech Inc | Adenocarcinoma; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Head and Neck Neoplasms; Hepatic Insufficiency; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Lip Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Mouth Neoplasms; Multiple Myeloma; Neoplasm Metastasis; Neoplasm, Residual; Neoplasms; Neoplasms, Unknown Primary; Nose Neoplasms; Oropharyngeal Neoplasms; Ovarian Neoplasms; Paranasal Sinus Diseases; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urogenital Neoplasms | Details |
| NTQ-1062 | NTQ-1062; NTQ1062 | Phase 3 Clinical | Nanjing Zhengda Tianqing Pharmaceutical Co Ltd | Breast Neoplasms; HR-positive breast cancer; Solid tumours | Details |
| SR-0379 | SR-0379 | Phase 3 Clinical | FunPep Co Ltd | Skin Ulcer | Details |
| Triciribine Phosphate | NSC-154020; PTX-002; API-2; TCN-P; VQD-002-ORAL; VQD-002; NSC-280594; PTX-200 | Phase 2 Clinical | National Cancer Institute | Breast Neoplasms; Hematologic Neoplasms; Leukemia; Neoplasms; Ovarian Neoplasms | Details |
| Miransertib | MK-7075; ARQ-092 | Phase 2 Clinical | Arqule Inc | Endometrial Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; PIK3CA-Related Overgrowth Spectrum; Proteus Infections; Proteus Syndrome; Solid tumours | Details |
| Ursolic Acid | NSC-167406; NSC-4060 | Phase 2 Clinical | University Of Guadalajara | Breast Neoplasms; Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Colonic Neoplasms; Colorectal Neoplasms; Insulin Resistance; Liver Neoplasms; Lung Neoplasms; Metabolic Syndrome; Muscular Atrophy; Pancreatic Neoplasms; Paraplegia; Prostatic Neoplasms; Quadriplegia; Sarcopenia; Spinal Cord Injuries; Stomach Neoplasms | Details |
| Uprosertib/Trametinib Dimethyl Sulfoxide | Phase 2 Clinical | Novartis Pharma Ag | Endometrial Neoplasms; Leukemia, Myeloid, Acute; Uterine Cervical Neoplasms | Details | |
| Selumetinib sulfate/MK-2206 | Phase 2 Clinical | Astrazeneca Plc, Merck & Co Inc | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rectal Neoplasms; Triple Negative Breast Neoplasms | Details | |
| Uprosertib | GSK-2141795; GSK-2141795C; UPB-795; LAE-003; GSK-795 | Phase 2 Clinical | Glaxosmithkline Plc, National Cancer Institute, Novartis Pharma Ag | Adenocarcinoma, Clear Cell; Breast Neoplasms; Endometrial Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Melanoma; Multiple Myeloma; Neoplasms; Skin Melanoma; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Uveal melanoma | Details |
| RX-0301 | RX-0201 nanoliposomal; RX-0201 Nano; HC0301; RX-0201-N; RX-0301; WGI-0301; RX-0201改良型 | Phase 2 Clinical | Rexahn Pharmaceuticals Inc | Carcinoma, Hepatocellular; Liver Neoplasms | Details |
| TER-2013 | TER-2013 | Phase 2 Clinical | Terremoto Biosciences Inc | Breast Neoplasms; Carcinoma, Squamous Cell; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms | Details |
| MK-2206 | MK2206; MK-2206; BIND-2206; NSC-749607 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Angioimmunoblastic T-cell Lymphoma; Bile Duct Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Breast Neoplasms; Breast Neoplasms, Male; Burkitt Lymphoma; Carcinoma, Adenoid Cystic; Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Central Nervous System Lymphoma; Cholangiocarcinoma; Chronic eosinophilic leukemia (CEL); Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Glioma; Hodgkin Disease; Intraocular Lymphoma; Kidney Neoplasms; Leukemia; Leukemia, Erythroblastic, Acute; Leukemia, Hairy Cell; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Mast-Cell; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myelogenous, | Details |
| HZB-0071 | HZB-0071 | Phase 1 Clinical | Heilongjiang Zbd Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd | Neoplasms | Details |
| Rupitasertib | DIACC3010; M-2698; MSC-2363318A; DIACC-3010 | Phase 1 Clinical | Emd Serono Inc | Breast Neoplasms; Glioblastoma; Solid tumours; Stomach Neoplasms | Details |
| CMX-2043 | LIP-EA; CMX-2043; R-LIP-EA-OH | Phase 1 Clinical | Ischemix Llc | Angina, Unstable; Brain Injuries, Traumatic; Cardiovascular Diseases; Coronary Artery Disease; Non-ST Elevated Myocardial Infarction | Details |
| TER-1754 | TER-1754 | Phase 1 Clinical | Terremoto Biosciences Inc | Telangiectasia, Hereditary Hemorrhagic | Details |
| Honokiol | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Gingival Diseases | Details | ||
| ATV-1601 | ATV-1601 | Phase 1 Clinical | Atavistik Bio Inc | Breast Diseases; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Urogenital Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |
| ALTA-2618 | ALTA-2618 | Phase 1 Clinical | Alterome Therapeutics Inc | Breast Neoplasms; Endometrial Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| TQB-3912 | TQB3912; TQB-3912 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Breast Neoplasms; HR-positive breast cancer; Neoplasms; Prostatic Neoplasms | Details |
| Hu-7691 | Hu-7691 | Phase 1 Clinical | Zhejiang University | Neoplasms; Solid tumours | Details |
| Oxysterols (Intsel Chimos) | Clinical | Centre National De La Recherche Scientifique (Cnrs) | Glioma | Details | |
| AKT1 inhibitors(Atavistik Bio Inc) | Clinical | Atavistik Bio Inc | Telangiectasia, Hereditary Hemorrhagic; Vascular Malformations | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Capivasertib | AZD-5363 | Approved | Astex Pharmaceuticals Inc, Cancer Research Technology, The Institute Of Cancer Research, London | Truqap, TRUQAP, 荃科得 | United States | Breast Neoplasms | Astrazeneca Pharmaceuticals Lp | 2023-11-16 | Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hormone-Sensitive Prostate Neoplasms; HR-positive breast cancer; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Metastatic breast cancer; Multiple Myeloma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |